Posted by Michael Wonder on 03 May 2026
Novartis receives Health Canada approval for Fabhalta oral treatment for adults with C3G
1 May 2026 - Novartis Pharmaceuticals Canada announced today that Health Canada has granted a Notice of Compliance for Fabhalta (iptacopan capsules) for the treatment of adult patients with C3 glomerulopathy (C3G) to reduce proteinuria.
The decision is supported by results from the Phase 3 APPEAR-C3G trial, a multi-centre, randomised, double-blind, placebo-controlled study.
